NCT00002924已完成不适用
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 184
- 试验地点
- 49
- 主要终点
- overall survival
研究概览
简要总结
RATIONALE: Gene mutations may make prostate cancer cells unable to attach to androgens. This may permit the growth of prostate cancer. Gene testing may improve the identification of patients with advanced prostate cancer.
PURPOSE: Clinical trial to study the androgen receptor gene in patients with prostate cancer that is not responsive to hormone therapy.
详细描述
OBJECTIVES:
- the feasibility of collecting bone marrow biopsies from prostate cancer patients in a cooperative group setting
- the incidence of marrow invasion by prostate tumor in random bone marrow biopsy
- the influence of previous prostate radiation on obtaining prostate tumor
- the frequency and type of AR mutations and
- association of AR mutations with response to antiandrogen withdrawal.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
overall survival
时间窗: Up to 10 years
次要结局
- response rate(Up to 10 years)
研究者
研究点 (49)
Loading locations...
相似试验
进行中（未招募）
不适用
Hormone-refractory Prostate cancer first Line Intermittent Taxotere and Estramustine. - NDProstate cancer.MedDRA version: 6.1Level: PTClassification code 10036909EUCTR2006-005728-17-ITAZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO128
进行中（未招募）
3 期
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate CancerProstate CancerNCT01368588Radiation Therapy Oncology Group2,590
已完成
3 期
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate CancerProstate CancerNCT00002651SWOG Cancer Research Network3,040
撤回
早期 1 期
Insulin Resistance Following ADT for Prostate CAProstate CancerInsulin ResistanceNCT04658849St. Louis University
Unknown
3 期
Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent ChemotherapyAdvanced Prostate CancerNCT01224405University of Turin, Italy600